Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

SciClone Pharmaceuticals

Request full access

A global specialty pharmaceutical company with a product portfolio of therapies for cancer and infectious diseases

Foster City, United StatesFounded 1990Biotech & Life Sciences

About SciClone Pharmaceuticals

SciClone Pharmaceuticals is a biopharmaceutical firm with an integrated platform for developing and commercializing pharmaceutical products. Founded in May 1990 by Thomas E. Moore and Nelson M. Schneider in California, the company initially aimed to acquire and develop pharmaceuticals for global marketing. SciClone's predecessor was listed on NASDAQ in March 1992. In 2017, the company underwent a privatization led by a consortium of Chinese investors, including GL Capital Management, and was subsequently delisted from NASDAQ in October 2017. A significant milestone was its official listing on the Main Board of the Hong Kong Stock Exchange on March 3, 2021, which raised approximately HK$2.2 billion. However, the company was later taken private again by GL Capital, with the privatization completed on July 3, 2024, for approximately US$1.13 billion.

The company's business model centers on the sale of its proprietary product, Zadaxin, alongside a portfolio of in-licensed and promoted products within Mainland China. Revenue is generated through the sale of these pharmaceutical products, distributed to hospitals and pharmacies. SciClone has strategically focused on high-growth therapeutic areas with unmet needs in China, particularly oncology and severe infections. Its proprietary product, Zadaxin (Thymalfasin), is a key revenue driver, used for treating hepatitis B and certain cancers, and has been noted for its role during the SARS and COVID-19 outbreaks. The company has also expanded its portfolio through in-licensing agreements, acquiring commercialization rights for products like Novartis's Zometa and The Medicines Company's Angiomax. A 'Go-To-Patient' (GTP) model has been implemented to extend sales beyond hospitals directly to pharmacies, significantly increasing patient accessibility. This business strategy involves acquiring licenses and participating in various stages of the product development lifecycle.

Under the leadership of President and CEO Hong Zhao, who joined in 2013, SciClone has focused on strategic transformation and operational excellence. Zhao, with over 30 years in the pharmaceutical industry and a background that includes senior roles at Novartis China and Simcere Pharmaceutical Group, has guided the company's shift towards an innovation-driven model. His leadership was instrumental in the 2021 Hong Kong IPO. The company's pipeline includes a range of drug candidates in various clinical stages, from early-stage IND filings to late-stage pivotal trials, addressing conditions such as solid tumors, pneumonia, and various cancers.

Source: Dealroom company data

At a glance

Status
Listed
Founded
1990
Headquarters
Foster City, United States
Listing
IPO 1992
Employees
119
Open positions
1
Dealroom signal
43.6/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Oncology, Biotech and Pharma, Hard Tech, DT and LS
Client focus
B2C
Investment activity
2 companies, latest Apr 2011
Capital deployed
—
Preferred round
ACQUISITION

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
IPO✓Exit Mar 2021 $279M $1.6B Undisclosed —
BUYOUT✓Exit Jun 2017 $605M $605M GL Capital —
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowthEBITDAMarginProfitMarginR&D
2026 $124M 0% −$1.2M -1% −$3.4M -2.7% $19M
2025 $124M +47.7% −$1.2M -1% −$3.4M -2.7% $19M
2024 $84M +33.4% $2.9M 3.5% −$423K -0.5% $15M
2023 $63M -83.4% $546K 0.9% $12M
2022 $378M +9.2% $162M 42.8%
2021 $346M +31.3% $161M 46.5%
2020 $264M — $133M 50.3%
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

SciClone Pharmaceuticals website traffic

Latest recorded traffic for SciClone Pharmaceuticals is 2K monthly website visits, up 412.8% over the last three months. SciClone Pharmaceuticals's team grew 33.7% over the past year.

Latest monthly visits2K 3-month web change+412.8% 1-year team growth+33.7%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

SciClone Pharmaceuticals in the Foster City ecosystem

Live from Dealroom

The SciClone Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • GL Capital

Other known investors1 additional known investor

  • Vivo Capital
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Foster City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about SciClone Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See SciClone Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.